Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily Grist

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
Nature Communications|May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancersChey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
Genome Medicine|September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancerEmily Grist, Stefanie Friedrich, Christopher Brawley, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
The Lancet. Digital Health|June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocolCharles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Prostate Cancer and Prostatic Diseases|January 11, 2022
Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomicsPhilip Sutera, Kim Van Der Eecken, Amar U Kishan, et al.
Nature Communications|May 6, 2020
Genomic landscape of platinum resistant and sensitive testicular cancersChey Loveday, Kevin Litchfield, Paula Z Proszek, et al.
Genome Medicine|September 4, 2022
Accumulation of copy number alterations and clinical progression across advanced prostate cancerEmily Grist, Stefanie Friedrich, Christopher Brawley, et al.
Lancet (London, England)|April 7, 2024
The Lancet Commission on prostate cancer: planning for the surge in casesNicholas D James, Ian Tannock, James N'Dow, et al.
The Lancet. Digital Health|June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocolCharles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Cell|August 27, 2025
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancersEmily Grist, Peter Dutey-Magni, Marina A Parry, et al.
Research Square|February 17, 2023
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trialMarina A Parry, Emily Grist, Larissa Mendes, et al.
The Lancet. Oncology|July 10, 2025
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocolSilke Gillessen, Laura Murphy, Nicholas D James, et al.
Pageof 2